Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Chezi Ganzel, MD, Judith Manola, MS, Dan Douer, MD, Jacob M. Rowe, MD, Hugo F Fernandez, MD, Elisabeth Paietta, Ph.D, Mark R. Litzow, MD, Ju-Whei Lee, Selina M Luger, MD, Hillard M. Lazarus, MD, Larry Cripe, MD, Martin M Oken, MD, Peter A Cassileth, MD, Martin S. Tallman, MD

Blood (2013) 122 (21): 63.

https://doi.org/10.1182/blood.V122.21.63.63

Published: 2013

Journal Articles

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

David H. Vesole, MD, PhD, Martin M Oken, MD, Charles Heckler, Philip R. Greipp, MD, Michael S Katz, BS., MBA, Susanna Jacobus, MS, Gary R Morrow, PhD, MS, On Behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 3017.

https://doi.org/10.1182/blood.V116.21.3017.3017

Published: 2010

Journal Articles

A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma

Mark P. Purdue, Qing Lan, Otoniel Martinez-Maza, Martin M. Oken, William Hocking, Wen-Yi Huang, Dalsu Baris, Betty Conde, Nathaniel Rothman

Blood (2009) 114 (13): 2730–2732.

https://doi.org/10.1182/blood-2009-04-217521

Published: 2009

Includes: Supplemental data

Journal Articles

Appraisal of immunoglobulin free light chain as a marker of response

Angela Dispenzieri, Lijun Zhang, Jerry A. Katzmann, Melissa Snyder, Emily Blood, Roberta DeGoey, Kimberly Henderson, Robert A. Kyle, Martin M. Oken, Arthur R. Bradwell, Philip R. Greipp

Blood (2008) 111 (10): 4908–4915.

https://doi.org/10.1182/blood-2008-02-138602

Published: 2008

Journal Articles

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

Natalia Gonzalez-Paz, Wee J. Chng, Rebecca F. McClure, Emily Blood, Martin M. Oken, Brian Van Ness, C. David James, Paul J. Kurtin, Kimberly Henderson, Gregory J. Ahmann, Morie Gertz, Martha Lacy, Angela Dispenzieri, Philip R. Greipp, Rafael Fonseca

Blood (2006) 109 (3): 1228–1232.

https://doi.org/10.1182/blood-2006-05-024661

Published: 2006

Journal Articles

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS

Wee Joo Chng, Scott A. Van Wier, Gregory J. Ahmann, Jerry M. Winkler, Syed M. Jalal, Peter Leif Bergsagel, Marta Chesi, Mike C. Trendle, Martin M. Oken, Emily Blood, Kim Henderson, Rafael Santana-Dávila, Robert A. Kyle, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Rafael Fonseca

Blood (2005) 106 (6): 2156–2161.

https://doi.org/10.1182/blood-2005-02-0761

Published: 2005

Journal Articles

Prognostic Value of Syndecan-1 in Multiple Myeloma and its Relationship with Other Prognostic Factors.

Shaji Kumar, MD, Emily Blood, Martin M. Oken, MD, Philip R. Greipp, MD

Blood (2004) 104 (11): 2402.

https://doi.org/10.1182/blood.V104.11.2402.2402

Published: 2004

Journal Articles

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

Rafael Fonseca, Carina S. Debes-Marun, Elisa B. Picken, Gordon W. Dewald, Sandra C. Bryant, Jerry M. Winkler, Emily Blood, Martin M. Oken, Rafael Santana-Dávila, Natalia González-Paz, Robert A. Kyle, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Philip R. Greipp

Blood (2003) 102 (7): 2562–2567.

https://doi.org/10.1182/blood-2003-02-0493

Published: 2003

Journal Articles

Clinical and biologic implications of recurrent genomic aberrations in myeloma

Rafael Fonseca, Emily Blood, Montserrat Rue, David Harrington, Martin M. Oken, Robert A. Kyle, Gordon W. Dewald, Brian Van Ness, Scott A. Van Wier, Kimberly J. Henderson, Richard J. Bailey, Philip R. Greipp

Blood (2003) 101 (11): 4569–4575.

https://doi.org/10.1182/blood-2002-10-3017

Published: 2003

Journal Articles

Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients

Anthony Calabro, Martin M. Oken, Vincent C. Hascall, Anna M. Masellis

Blood (2002) 100 (7): 2578–2585.

https://doi.org/10.1182/blood-2002-01-0030

Published: 2002

Journal Articles

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients

Rafael Fonseca, Emily A. Blood, Martin M. Oken, Robert A. Kyle, Gordon W. Dewald, Richard J. Bailey, Scott A. Van Wier, Kimberly J. Henderson, James D. Hoyer, David Harrington, Neil E. Kay, Brian Van Ness, Philip R. Greipp

Blood (2002) 99 (10): 3735–3741.

https://doi.org/10.1182/blood.V99.10.3735

Published: 2002

Journal Articles

The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance

Rafael Fonseca, Martin M. Oken, Philip R. Greipp

Blood (2001) 98 (4): 1271–1272.

https://doi.org/10.1182/blood.V98.4.1271

Published: 2001

Journal Articles

Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients

Neil E. Kay, Tracy L. Leong, Nancy Bone, David H. Vesole, Philip R. Greipp, Brian Van Ness, Martin M. Oken, Robert A. Kyle

Blood (2001) 98 (1): 23–28.

https://doi.org/10.1182/blood.V98.1.23

Published: 2001

Journal Articles

Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience: Presented in part at the American Society of Hematology meeting, New Orleans, LA, December 1999.

Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J. Francois, Elisabeth Paietta, Peter H. Wiernik, Gordon Dewald, Peter A. Cassileth, Martin M. Oken, Jacob M. Rowe

Blood (2000) 96 (7): 2405–2411.

https://doi.org/10.1182/blood.V96.7.2405

Published: 2000

Journal Articles

Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group

Philip R. Greipp, Traci Leong, John M. Bennett, Jean P. Gaillard, Bernard Klein, James A. Stewart, Martin M. Oken, Neil E. Kay, Brian Van Ness, Robert A. Kyle

Blood (1998) 91 (7): 2501–2507.

https://doi.org/10.1182/blood.V91.7.2501

Published: 1998

Journal Articles

BCL-2 Expression Correlates With Lower Proliferative Activity in the Intermediate- and High-Grade Non-Hodgkin's Lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study

Jane N. Winter, Janet Andersen, John C. Reed, Stanislaw Krajewski, Daina Variakojis, Kenneth D. Bauer, Richard I. Fisher, Leo I. Gordon, Martin M. Oken, Shuwei Jiang, David Jeffries, Peter Domer

Blood (1998) 91 (4): 1391–1398.

https://doi.org/10.1182/blood.V91.4.1391

Published: 1998

Journal Articles

Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial

Neil E. Kay, Traci Leong, Robert A. Kyle, Philip Greipp, Daniel Billadeau, Brian Van Ness, Nancy Bone, Martin M. Oken

Blood (1997) 90 (1): 340–345.

https://doi.org/10.1182/blood.V90.1.340

Published: 1997

Journal Articles

Spherocytic Hemolytic Disease During Magnesium Deprivation in the Rat

MARTIN M. OKEN, MAJOR, M.D., M.C., MARSHALL A. LICHTMAN, M.D., DENIS R. MILLER, M.D., PIERRE LEBLOND, M.D.

Blood (1971) 38 (4): 468–478.

https://doi.org/10.1182/blood.V38.4.468.468

Published: 1971

NARROW

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma

Appraisal of immunoglobulin free light chain as a marker of response

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS

Prognostic Value of Syndecan-1 in Multiple Myeloma and its Relationship with Other Prognostic Factors.

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

Clinical and biologic implications of recurrent genomic aberrations in myeloma

Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients

The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance

Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients

Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience: Presented in part at the American Society of Hematology meeting, New Orleans, LA, December 1999.

Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group

BCL-2 Expression Correlates With Lower Proliferative Activity in the Intermediate- and High-Grade Non-Hodgkin's Lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study

Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial

Spherocytic Hemolytic Disease During Magnesium Deprivation in the Rat

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only